IOVANCE BIOTHERAPEUTICS, INC. Uncategorized Contracts & Agreements
22 Contracts & Agreements
- Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Plan (Filed With SEC on May 9, 2024)
- Open Market Sale Agreement dated June 16, 2023, by and between Iovance Biotherapeutics, Inc. and Jefferies LLC (Filed With SEC on June 16, 2023)
- Open Market Sale Agreement dated November 18, 2022, by and between Iovance Biotherapeutics, Inc. and Jefferies LLC (Filed With SEC on November 18, 2022)
- Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Plan (Filed With SEC on February 24, 2022)
- Iovance Biotherapeutics, Inc. 2021 Inducement Plan (Filed With SEC on September 23, 2021)
- Open Market Sale Agreement dated February 8, 2021, by and between Iovance Biotherapeutics, Inc. and Jefferies LLC (Filed With SEC on February 9, 2021)
- First Amendment dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc. and Hudson Skyway Landing, LLC (Filed With SEC on February 9, 2021)
- Second Amendment dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc. and Hudson Skyway Landing, LLC (Filed With SEC on February 9, 2021)
- Description of Securities (Filed With SEC on February 25, 2020)
- Second Amendment to the Strategic Alliance Agreement between Iovance Biotherapeutics, Inc., and The University of Texas M.D. Anderson Cancer Center, effective February 16, 2018 (Filed With SEC on March 12, 2018)
- First Amendment to the Strategic Alliance Agreement between Lion Biotechnologies, Inc., and The University of Texas M.D. Anderson Cancer Center, effective August 2, 2017 (Filed With SEC on March 12, 2018)
- PLANOF CONVERSION OF LION BIOTECHNOLOGIES, INC. A Nevada Corporation INTO LION BIOTECHNOLOGIES, INC. A Delaware Corporation (Filed With SEC on June 2, 2017)
- AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENTAGREEMENT (Filed With SEC on July 1, 2016)
- BOARD ADVISER AGREEMENT (Filed With SEC on June 3, 2016)
- NATIONAL INSTITUTES OF HEALTH FIRST AMENDMENT TO L-107-2015/0 (Filed With SEC on November 6, 2015)
- AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENTAGREEMENT (Filed With SEC on April 17, 2015)
- Text MarkedBy [* * *] Has Been Omitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities AndExchange Commission. THENational Institutes... (Filed With SEC on March 16, 2015)
- MATURITY DATE EXTENSION (Filed With SEC on October 4, 2012)
- MATURITY DATE EXTENSION (Filed With SEC on July 6, 2012)
- LETTER OF INTENT (Filed With SEC on November 21, 2011)
- GENESIS BIOPHARMA, INC. OPTION CERTIFICATE (Filed With SEC on October 20, 2011)
- DATED 15TH MARCH2010 (1)CANCER RESEARCH TECHNOLOGY LIMITED AND (2)GENESIS BIOPHARMA, INC. (Filed With SEC on July 6, 2010)
